Strides Shasun

Motilal Oswal is bullish on Strides Shasun has recommended buy rating on the stock with a target price of Rs 481 in its research report dated August 08, 2018.

Buy Strides Shasun; target of Rs 480: HDFC Securities

HDFC Securities is bullish on Strides Shasun has recommended buy rating on the stock with a target price of Rs 480 in its research report dated 09 Aug 2018.

Strides Shasun stock gains 2% on USFDA approval for painkiller drug

Ibuprofen is used to relieve pain from various conditions such as headache, dental pain, muscle aches, or arthritis.

Strides Shasun gets WHO pre-qualification for its rectal artesunate product

Strides Shasun has received pre-qualification from the World Health Organization (WHO) for its rectal artesunate product for the pre-referral management of severe malaria.

Strides Shasun seeks shareholders' nod to change name to Strides Pharma Science

In November 2015, Strides Arcolab had changed its name to Strides Shasun post amalgamation of Shasun Pharmaceuticals with Strides Arcolab.

Buy Strides Shasun; target of Rs 530: JM Financial

JM Financial is bullish on Strides Shasun has recommended buy rating on the stock with a target price of Rs 530 in its research report dated May 21, 2018.

Buy Strides Shasun; target of Rs 980: HDFC Securities

HDFC Securities is bullish on Strides Shasun has recommended buy rating on the stock with a target price of Rs 980 in its research report dated May 10, 2018.

Market Update: GMR Infra, Voltas drag Midcap index down; Strides Shasun plunges 20%

The most actively traded stocks on the NSE were Bajaj Finance, up over 4 percent, and Reliance Communications, which plunged over 10 percent.

Strides Shasun Q4 consolidated loss from continuing operations at Rs 4.4 cr

Revenue from operations fell by 1.9 percent year-on-year to Rs 664.2 crore for the quarter ended March 2018.

Strides Shasun plunges 23% after consolidated loss from continuing operations in Q4

Other income during the quarter fell sharply to Rs 21.8 crore compared to Rs 62.4 crore in Q4FY17.

Strides Shasun to divest API arm to Solara for Rs 131 cr

The company's board today approved divestment of its 100 per cent shareholding in Strides Chemicals to Solara, Strides Shasun said in a regulatory filing.

Strides Shasun gains 2% on USFDA approval for antihistamine drug

Cyproheptadine hydrochloride tablets is a generic version of Periactin tablets of Merck & Co Inc.

Strides Shasun likely to test Rs 788 in 9-12 months: Akash Jain

"The company’s market share in Q3FY18 quarter was 33 percent, which is up 6 percent points compared to what it reported last quarter," Akash Jain, Vice-president, Equity Research at Ajcon Global Services.

Strides Shasun gets USFDA nod for generic Ibuprofen capsules

The company's wholly-owned subsidiary Strides Pharma Global has received approval for Ibuprofen capsules in the strength of 200 mg from the United States Food & Drug Administration (USFDA), Strides Shasun said in a statement.

Nifty likely to face stiff resistance at 10,490; top 5 stocks which can give up to 5% return in short term

"Till Nifty holds 10,350 levels decisively, bounce back from lower levels cannot be ruled out and on higher end stiff hurdle seen around 10,490 mark," says Rajesh Agarwal of AUM Capital.

Strides Shasun gets USFDA nod for HIV treatment drug

The approval granted to the company's wholly-owned subsidiary Strides Pharma Global Pte by the US Food and Drug Administration (USFDA) is for Efavirenz tablets of 600 mg strength, the company said in a regulatory filing.

Strides Shasun to launch Ranitidine tablets in US

Strides is already a key player in the US Ranitidine Rx market with 32 per cent market share through its approval for Ranitidine Tablets USP, 150 mg and 300 mg. The new launch will further strengthen company’s Ranitidine franchise, the company said in a statement.

Top buy & sell ideas by Ashwani Gujral, Mitessh Thakkar & Prakash Gaba for February 22

Ashwani Gujral of ashwanigujral.com recommends buying Tech Mahindra with a stop loss of Rs 588, target of Rs 620, a buy on NIIT Tech with a stop loss of Rs 788, target of Rs 825 while a sell call on Century Textiles with a stop loss of Rs 1190, target of Rs 1130.

Strides Shasun arm gets USFDA nod for HIV drug

In a BSE filing, it said Strides Pharma Global Pte. has received approval from the United States Food and Drug Administration (USFDA) for tenofovir disoproxil fumarate tablets, 300 mg.

Top 12 stocks which gave multibagger returns as Nifty rose from 10,000 to 11,000

Most experts are calling this to be a pre-budget rally and the euphoria is tied up to the Budget, and thankfully the December quarter earnings have not been bad in fact some of them were better than estimates.

Buy Reliance Industries, Torrent Power, Strides Shasun; sell Union Bank of India: Sudarshan Sukhani

Sudarshan Sukhani of s2analytics.com is of the view that one can buy Reliance Industries, Torrent Power and Strides Shasun and can sell Union Bank of India.

Strides Shasun buys controlling stake in South African drug co Trinity Pharma for Rs 27.5 cr

The transaction provides access to pipeline of more than 110 product dossiers already submitted in addition to an important platform for Strides' ARV launch in the large, prive non-tender market in South Africa.

Strides acquires controlling stake in South Africa's Trinity

"Strides Pharma Asia Pte, Singapore, a wholly-owned subsidiary of Strides Shasun has entered into definitive agreements with Trinity Pharma Proprietary, South Africa for acquisition of controlling stake in Trinity," Strides Shasun said in a BSE filing.

Buy Strides Shasun; target of Rs 1200: HDFC Securities

HDFC Securities is bullish on Strides Shasun has recommended buy rating on the stock with a target price of Rs 1200 in its research report dated 21 November 2017.